In short
Soquelitinib is an investigational selective inhibitor of the enzyme ITK (interleukin-2-inducible T cell kinase), a chemical substance being studied for its effects on the immune system. One authorised Phase 2 trial is evaluating soquelitinib in 202 participants with moderate to severe atopic dermatitis (AD). The trial compares three oral dosing regimens of soquelitinib against placebo, measuring changes in the EASI score, a standard measure of eczema severity.
Key points
- Soquelitinib is a selective ITK inhibitor that modulates T cell immune responses.
- One Phase 2 trial is authorised for soquelitinib in moderate to severe atopic dermatitis.
- The trial plans to enroll 202 participants and compares three oral dosing regimens against placebo.
- The primary outcome is the percent change in EASI score from baseline at Week 12.
- Soquelitinib is investigational, with no marketing authorisation described in the provided records.
What is soquelitinib?
Soquelitinib is an investigational selective inhibitor of the enzyme ITK (interleukin-2-inducible T cell kinase). It is a chemically synthesised small-molecule substance developed to modulate T cell immune responses. Soquelitinib has no marketing authorisation described in the provided records and remains an investigational medicine being studied in clinical trials.
How does soquelitinib work?
Soquelitinib selectively inhibits ITK, an enzyme involved in T cell signalling and immune function. By blocking ITK, soquelitinib modulates T cell activity and alters immune responses relevant to inflammatory conditions and tumour immunity. ITK inhibition is being explored as a way to influence immune-mediated disease processes.
Which conditions is soquelitinib studied for?
- Atopic dermatitis (AD) — a chronic inflammatory skin condition characterised by itchy, inflamed skin; the authorised Phase 2 trial is evaluating soquelitinib in participants with moderate to severe AD.
How is soquelitinib given?
Soquelitinib is given by mouth as tablets. The authorised trial uses oral doses of 200 mg once daily, 200 mg twice daily, and 400 mg once daily, compared with placebo tablets.
What do the clinical trials show?
There is one authorised Phase 2 trial of soquelitinib, in moderate to severe atopic dermatitis, with a planned enrollment of 202 participants. The trial is interventional and placebo-controlled, comparing three oral dosing regimens of soquelitinib (200 mg once daily, 200 mg twice daily, and 400 mg once daily) against placebo.
The primary outcome is the percent change from baseline in the EASI score (Eczema Area and Severity Index) at Week 12. The EASI score measures the extent and severity of eczema on the skin. The trial status is authorised, meaning it has received approval to proceed but results are not yet reported in the registry.
What side effects are known?
The provided sources do not report specific side effects of soquelitinib. No side effect information is available from the trial registry record or the supplementary source.